Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The only evaluated claims concern retail pricing, which is absent from the supplied FDA-approved prescribing information. Therefore, there is no on-label content to confirm or contradict; the claims are simply unsupported by the label.
Category Scores
Accurate Statements
Unsupported Statements
Humira (adalimumab) 40 mg pen has a typical approximate U.S. retail price of about $3,600–$4,200 per month (about $90–$105 per dose) without insurance.
Retail pricing/cost-per-dose estimates are absent from the FDA-approved prescribing information.
Humira (adalimumab) 80 mg pen has a typical approximate U.S. retail price of about $7,200–$8,400 per month (about $180–$210 per dose) without insurance.
Retail pricing/cost-per-dose estimates are absent from the FDA-approved prescribing information.
Contradictions
Important Omissions
Any FDA-label-supported information relevant to Humira dosing, administration, contraindications, warnings/precautions, interactions, or adverse reactions (none were provided in the claims).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims are financial (retail pricing) and do not directly affect dosing, contraindications, or safety information described in the label. They remain unsupported by labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Pricing/cost-per-dose assertions are not supported by FDA-approved Humira prescribing information.
Suggested Improvement
Remove or replace the retail pricing estimates with information that is supported by the provided label or clearly label the content as non-prescribing-information (non-label) data.